Reply to Gan et al., to Calzetta et al., and to Poor

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (The ENHANCE Trials)

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)226-228
Number of pages3
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume209
Issue number2
DOIs
StatePublished - Jan 15 2024

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this